Ad
BLUE - bluebird bio Stock Trading
About | bluebird bio Inc. (NASDAQ:BLUE)
Not available
Quote | bluebird bio Inc. (NASDAQ:BLUE)
| Last: | $2.86 |
|---|---|
| Change Percent: | -6.03% |
| Open: | $5.1 |
| Close: | $2.86 |
| High: | $5.53 |
| Low: | $2.69 |
| Volume: | 52,219,517 |
| Last Trade Date Time: | 12/08/2023 03:00:00 am |
News | bluebird bio Inc. (NASDAQ:BLUE)
-
The recent 4-year partnership between Pfizer and Beam Therapeutics involves $300 million upfront to speed validation of the technology and an additional $1.05 billion in milestone payments. A recent amended agreement between Verve Therapeutics and Beam Therapeutics is a target swap th...
-
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...
Message Board Posts | bluebird bio Inc. (NASDAQ:BLUE)
| Subject | By | Source | When |
|---|---|---|---|
| I have a similar position - 98,050 in | Moose412 | investorshub | 04/27/2023 7:08:18 AM |
| FYI | stocksrising | investorshub | 04/24/2023 11:53:50 AM |
| Here is an example from a few accounts | stocksrising | investorshub | 04/20/2023 11:46:16 AM |
| You picked up 90k shares since September? | Moose412 | investorshub | 04/20/2023 8:33:02 AM |
| I have ~100,000 reasons why Im hoping | stocksrising | investorshub | 04/18/2023 9:52:26 PM |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 years ...
-
Bluebird Bio, Inc. (NASDAQ: BLUE) shares are trading higher Friday after Morgan Stanley upgraded Bluebird Bio from Underweight to Equal-Weight and ...
-
U.S. stocks traded mostly higher, with the Dow Jones index gaining more than 40 points on Friday. Shares of Torrid Holdings Inc. (NYSE: CURV) share...